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 Implication for health policy/practice/research/medical education:
As Egypt is a country of intermediate prevalence regarding HBV and of high prevalence regarding HCV infection, great effort 
should be made to prevent and control these infections .updating the knowledge about the prevalence of these infections particu-
larly among the high risk groups is important to assess the efficacy of preventive measures and to highlight weak points in the 
strategy aiming to decrease the infection rate. This study is recommended to all clinicians involved in treatment of  polytransfused 
patients for better outcome.
Background: Despite progress made in the prevention of transfusion-transmitted infec-
tions (TTI) over the last few years, they continue to be a problem in many parts of the 
world, particularly in multitransfused patients.
Objectives: The aim of this study was to estimate the prevalence of hepatitis B virus 
(HBV), hepatitis C virus (HCV), and to evaluate the screening and vaccination program 
among our cohort of multitransfused children from Qena, Upper Egypt.
Patients and Methods:  One-hundred  children  suffering  from  diseases  requiring  re-
peated blood transfusions were included in the study. They were classified into group 1, 
which included 67 children with thalassemia, and group 2, which included 33 children 
with hemophilia. Screening for hepatitis B surface antigen, hepatitis B surface antibody, 
hepatitis B core antibody and antibody to HCV was done using a second-generation en-
zyme-linked immunosorbent assay technique.
Results: Only 12% of all patients were either acutely or chronically infected with HBV. 46% 
were immune due to previous vaccination, whereas 39% of patients were not protected 
from HBV infection. HCV antibodies were positive in 45% of cases. Seventy-eight patients 
had a complete hepatitis B vaccination in the form of three doses as documented by 
birth certificate. Thirty-six patients mentioned history suggestive of hepatitis. The prev-
alence of the studied hepatitis markers was similar in both the thalassemia and hemo-
philia groups of children.
Conclusions: Transfusion-transmitted hepatitis is still a major problem for multitrans-
fused children in Egypt. More effort is required to reduce the infection rate through 
proper screening of blood and blood products, strict emphasis on receiving the vaccine, 
regular follow-up for those children with a hepatitis B antibody titer, and providing 
booster doses for those in need. Copyright  c 2012 Kowsar Corp. All rights reserved.
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1. Background
Regular blood transfusions improve the overall surviv-
al of multitransfused children but despite the progress 
made in preventing transfusion-transmitted infections 
(TTIs) over the last few years, TTIs continue to be a prob-
lem in many parts of the world (1). Blood transfusion is 
the main risk factor for transmitting viral hepatitis, par-
ticularly in patients with hematological diseases (2).The 
TTI problem is directly proportional to the prevalence 
of infection in the blood donor community (3). Patients 
with thalassemia commonly receive transfusions and, 
thus, are exposed to transfusion-associated infections. 
Among these infections, hepatitis B and hepatitis C are 
the most common (4). Hepatitis B is an important in-
fection in patients with thalassemia and prevention by 
vaccination is necessary. The immunological response 
to hepatitis B vaccine in polytransfused patients with 
thalassemia requires additional research attention (5). 
Although the risk of post-transfusion hepatitis C virus 
(HCV) infection dropped significantly after the national 
screening of blood in 1993, more than 20% of children 
who were multitransfused after that date were HCV-RNA 
positive (6). Monitoring infectivity markers in multi-
transfused patients is an important indicator of the effi-
ciency and quality of testing in blood centers (7). 
2. Objectives
The objective of the study was to estimate the preva-
lence of hepatitis B virus (HBV) and HCV antibodies 
among multitransfused children registered at the blood 
bank of Red Crescent Hospital in Qena (Upper Egypt) to 
update the prevalence of HBV and HCV infections among 
multitransfused children and to evaluate the impact of 
serological screening and the vaccination program on 
the prevalence of those infections. 
3. Patients and Methods
This cross-sectional study included 100 children at-
tending the children’s blood bank established to serve 
children at Red Crescent Hospital. The children were suf-
fering from diseases that require repeated blood trans-
fusions. This study was conducted according to the rec-
ommendations of the Ethics Committee of Children’s 
Hospital, Ain Shams University. Informed consent was 
obtained from the children’s guardians. Among the 100 
included patients, 67 had thalassemia and constituted 
group 1, 33 patients were hemophiliacs and constituted 
group 2. The groups were subjected to a complete his-
tory stressing the duration of transfusion therapy, blood 
source (Red Crescent blood bank or multiple centers), 
frequency of transfusion, history of vaccination against 
hepatitis B, and a history suggestive of hepatitis. A thor-
ough clinical examination was performed, emphasizing 
the presence or absence of jaundice and size of the liver 
and spleen. Five cc of venous blood was collected from 
each patient during regular follow-up using a sterile 
plastic syringe. One cc was mixed with EDTA and used for 
a complete blood count (CBC). The blood samples were 
centrifuged for 10 minutes. The remaining serum was 
used to measure aspartate transaminase (AST), alanine 
transaminase (ALT), and total and direct bilirubin lev-
els. The remaining serum was placed in sterile covered 
storage tubes and stored at −30°C until collection of all 
samples. Screening for the hepatitis B surface antigen 
(HBsAg), hepatitis B surface antibody, and hepatitis B 
core antibody (HBc Ab) was conducted using a second-
generation enzyme-linked immunosorbent assay (ELISA) 
technique with commercial kits provided by ADALTIS 
(Guidonia di Montecelio, Rome, Italy) Screening for an-
tibody to HCV (anti-HCV) was performed using a second 
generation ELISA technique with commercial kits provid-
ed by Diasorin (Saluggia (Vercelli), Italy).
3.1. Statistical Analysis
Descriptive and analytical statistics were performed 
using the Excel 2003 software package (Microsoft Inc., 
Redmond, WA, USA). Data are presented as mean ± SD 
and range. Categorical data are presented as numbers 
and percentages. Comparisons between the groups were 
made using the Mann-Whitney U-test for non-parametric 
data (z-values). Associations between categorical param-
eters were performed with the chi-square test. Values of P 
< 0.05 were considered significant. 
4. Results
The patients included in the study ranged in age from 
4–15 years with a mean of 8.29 ± 3.16 years. There were 68 
(68%) males and 32 (32%) females. Their disease duration 
ranged from 2 to 13 years with a mean of 6.45 ± 3.11 years. 
Children with thalassemia were treated with transfu-
sions of packed red blood cells (RBCs), chelation therapy, 
and a splenectomy, if indicated. Children with hemophil-
ia received either fresh frozen plasma or cryoprecipitate. 
The transfused blood or blood product units (packed 
RBCs unit = 300 ml, plasma unit = 250 ml, and cryopre-
cipitate unit = 15 ml) ranged from 16 to 149 units with a 
mean of 66.90 ± 33.69 units through the entire disease 
duration. Forty-four patients received blood or blood 
products from the Red Crescent blood bank at Qena, and 
56 patients (56%) received blood from multiple centers. 
Seventy-eight patients had complete hepatitis B vaccina-
tions in the form of three doses as documented by birth 
certificate, and 22 patients (22%) had incomplete vacci-
nation of hepatitis B (missing one or two doses). Thirty-
six patients mentioned a history suggestive of hepati-
tis. Fifty-one of the patients were on chelation therapy 
due to high serum ferritin levels (>1000 ng/dl), and 23 
patients (23%) were splenectomized, as they were all di-288 Hepat Mon. 2012;12(4)
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agnosed with thalassemia. As shown in Table 1, 12% of all 
patients were positive for HBsAg and were either acutely 
(5%) or chronically (7%) infected with hepatitis B. In total, 
46 patients were immune due to vaccination and three 
were immune due to previous infection, whereas 39% 
of patients were not protected from HBV infection. HCV 
antibodies were positive in 45 cases and coinfection by 
hepatitis B and C was present in 12. Eight males and four 
females were positive for HBsAg. Their mean age was 11.2 
± 3.3 years with a mean disease duration of 8.5 ± 3 years. 
Seven/12 were not completely vaccinated. Thirty-two 
males and 13 females had positive HCV antibodies. Their 
mean age was 7.7 ± 2.8 years with a mean disease dura  -
tion of 3.5 ± 1.9 years. Children positive for HBsAg were 
significantly older than those who were positive for HCV 
(P < 0.001). They also had a longer disease duration (P < 
0.001) and received more blood or blood products units 
(P < 0.05).
No relationship was found with the blood source.
Patients were classified into two groups. Group 1 includ-
Hepatitis Markers Cases, No. (%) (n=100) Significance
HBs Ag: negative
HBs Ab: positive
HBc Ab: negative
46 (46) Indicating Immunity because of hepatitis B vaccination
HBs Ag: positive
HBs Ab: positive
HBc Ab: negative
7(7) Indicating chronic infection
HBs Ag: positive
HBs Ab: negative
HBc Ab: positive
5(5) Indicating that they are acutely infected
HBs Ag: negative
HBs Ab: positive
HBc Ab: positive
3(3) Immune because of natural infection
HBs Ag: negative
HBs Ab: negative
HBc Ab: negative
39(39) Susceptible (not immune) to HBV infection
HCV Ab: positive 45(45) Indicating recent or past infection with HCV 
Positive for both HBs Ag and HCV Ab  12(12) Have co infection 
Table 1. Hepatitis Markers For the Studied Cases
Group 1 Group 2  P value
Age, y, mean ± SD 7.64 ± 2.93 8.94 ± 3.29 < 0.05
Disease duration, y, mean ± SD 5.62 ± 2.63 7.27 ± 3.35  < 0.05
Received blood, units, mean ± SD 50.94 ± 23.57 82.86 ± 34.92   < 0.001
AST, IU/L, mean ± SD 32.14 ± 21.11 47.32 ± 24.40 < 0.05
ALT, IU/L, mean ± SD 35.84 ± 19.09 47.70 ± 29.42 > 0.05
T bilirubin, mg/dL, mean ± SD 2.90 ± 1.16 2.26 ± 0.91 < 0.05
D bilirubin, mg/dL, mean ± SD 1.06 ± 0.74 1.42 ± 0.76 < 0.05
Indirect bilirubin, mg/dL, mean ± SD 1.84 ± 0.95 0.84 ± 0.57 < 0.001
Source of transfused blood, No. (%) > 0.05
RCB a only
multiple sources
31 (46)
36 (54)
13 (39)
20 (61)
History of HB Vaccination, No. (%) > 0.05
Incomplete
Complete
12 (18)
55 (82)
9 (27)
24 (73)
History suggestive of hepatitis > 0.05
Negative
Positive
42 (63)
25 (37)
22 (67)
11 (33)
Table 2. Clinical and Laboratory Studies of the Two Groups
a Abbreviations: RCB, Red Crescent blood bank289 Hepat Mon. 2012;12(4)
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Hepatitis Markers Interpretation Group 1, No. (%) (n = 67), Group 2, No. (%) (n = 33) P value 
HBs Ag: Negative Immune due to vaccination against HBV 31 (46) 15 (46) > 0.05
HBs Ab: Positive
HBc Ab: Negative
HBs Ag: Positive Chronically infected  3 (4) 4 (12) > 0.05
HBs Ab: Positive
HBc Ab: Negative
HBs Ag: Positive Acutely infected  3 (4) 2 (6) > 0.05
HBs Ab: Negative
HBc Ab: Positive
HBs Ag: Negative Immune due to natural infection 2 (3) 1 (3) > 0.05
HBs Ab: Positive
HBc Ab: Positive
HBs Ag: Negative Not immune, at risk & need vaccination 28 (42) 11 (33) > 0.05
HBs Ab: Negative
HBc Ab: Negative
HCV Ab: Positive Recent or past infection with HCV. 32 (48) 13 (39) > 0.05
HBs Ag & HCV Ab Coinfection 7 (10) 5 (15) > 0.05
Table 3. Viral Markers in the Two Groups
ed 67 patients with ß-thalassemia and group 2 included 
33 patients with hemophilia. Table 2 shows a comparison 
of the studied parameters between the two groups.
Patients in group 2 were significantly older and had a 
prolonged disease duration compared to those in group 
1. Significantly more blood or blood products units were 
received by group 2 patients compared to those in group 
1 (P < 0.001). AST (IU/L) and direct bilirubin (mg/dl) were 
significantly higher in group 2 than those in group 1, 
whereas significantly higher total bilirubin (mg/dl) (P 
< 0.05) and indirect bilirubin (mg/dl) (P < 0.001) levels 
were observed in group 1 compared to those in group 2 
(Table 2).
The prevalence of the hepatitis markers was similar in 
the thalassemia and hemophilia groups of children (Ta-
ble 3).
5. Discussion
In 1992, Egypt started a universal immunization pro-
gram in infants. The schedule adopted by the Egyptian 
Ministry of Health was three doses of yeast-recombinant 
hepatitis B vaccine administered to all infants at 2, 4, and 
6 months to coincide with other compulsory vaccines 
(8). However, complete hepatitis B vaccination in our 
study (as documented by birth certificate) was achieved 
in 78 patients, whereas 22 patients had incomplete vac-
cination (missed one or two doses). This result suggests 
that the vaccination schedule requires additional effort 
to ensure that the entire population has strictly complet-
ed their vaccinations, particularly in the high-risk groups 
of patients. We also found that among all polytransfused 
children in our study that one-third of those who com-
pleted their vaccinations were not protected. This could 
be explained by the fact that a certain percentage of those 
who received vaccinations will be non-responsive or hy-
poresponsive to the HBV vaccine; this is particularly true 
for patients with chronic liver disease (9), renal disease, 
or patients undergoing hemodialysis, as these patients 
lose hepatitis B immunity after natural infection or vac-
cination (10). The prevalence of HbsAg in polytransfused 
patients was high before the era of vaccination, as shown 
in different studies, and it varies in different places ac-
cording to prevalence in the community. Amarapurkar 
et al. (11) studied children with thalassemia for HBsAg 
in India in 1992. The results were positive in 45% of their 
patients. In 1993, a study among Egyptian children with 
thalassemia showed that HBsAg positivity was 16.48% (12). 
After establishing a vaccination program against hepa-
titis B, there was a notable impact on the prevalence of 
hepatitis B infection rate. Al-Shayyab et al. (13) showed HB-
sAg seropositivity in 3.5% of patients with hereditary he-
molytic anemia in a study conducted in Jordan in 2001i. 
Irshad et al. (14) reported that 18% of children with thalas-
semia were positive for HBsAg in India in 2002. In 2005, 
Khakhkhar and Joshi (15) conducted a study on children 
with thalassemia also in India and found that only 6.6% 
were positive for HBsAg. A very low prevalence of posi-
tive HBsAg was found in multi-transfused patients with 
β-thalassemia major or intermedia and sickle cell anemia 
in a 2006 Turkish study by Ocak et al. (16), as only 0.75% 
were HBsAg positive. Among 50 patients with thalas-
semia, hepatitis B virus infection occurred in one patient 
(2%) in Cairo in 2009 (17). 290 Hepat Mon. 2012;12(4)
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The decrease in the prevalence of hepatitis B infection 
reflects the efficacy of the vaccination program and effec-
tive screening of blood and blood products. Despite the 
decline in the prevalence of HBsAg among Egyptian poly-
transfused children over the past 20 years, it is still high 
compared to other geographical areas, and this could be 
attributed to the high infection rates among those chil-
dren despite vaccination against HBV, as they might not 
have responded adequately to vaccination or may not 
be fully vaccinated. Post-vaccination infections may be 
a result of viruses harboring surface (S)-gene mutations 
in a region critical for antibody reactivity to the hepati-
tis B surface antigen (anti-HBs). Furthermore, the burden 
of infection in the community plays a role, as Egypt has 
intermediate levels of HBV infection (2–7% chronic infec-
tion) (18). Although blood is screened for HBV in blood 
banks in Egypt, blood-related HBV transmission may oc-
cur, because screening in most blood banks is performed 
only for HBsAg but not for core antibodies or ALT. El Za-
yadi et al. (19) called for implementing the anti-HBc test 
as a routine assay, which would certainly eliminate pos-
sible HBV-infected blood units, as rejection of these units 
would be beneficial to decrease the risk of HBV transmis-
sion, particularly in immunocompromised recipients. 
Several published studies have reported the prevalence 
of HCV among polytransfused patients in different areas 
over the world. Khalifa et al. (20) reported HCV preva-
lence of 85% in Egypt in 1993, and the prevalence of HCV 
in Egypt in 1997 was 69% among polytransfused children 
and 55% among blood donors (21). The prevalence of HCV 
positivity in New Delhi in 1998 was 57% (22). In Denmark, 
56% of polytransfused patients were HCV positive in 2002 
(23), whereas in Iran Ansar et al. (24) found HCV antibod-
ies in 63.8% of their polytransfused patients. The reported 
prevalence of hepatitis C antibodies in Italy was 40.7% in 
2002 (25). Darwish et al. (26) studied the geographic dis-
tribution of HCV sero-positivity in patients with thalas-
semia in Egypt and found that 46.2% in the Delta region 
were HCV positive, which is the highest prevalence in 
Egypt compared to 38.6% in Big Cairo and 37.8% in Upper 
Egypt. In Iran in 2008, 16.9% of children with thalassemia, 
were anti-HCV positive (27), whereas in Khuzestan Prov-
ince, southwest Iran, 28.1% of patients with thalassemia 
were HCV positive in 2009 (28). However, the HCV preva-
lence was 41.7% in a study by Hussain et al. (29) conducted 
in Pakistan in 2008. In the Middle East, the prevalence of 
HCV among patients with thalassemia has been remark-
ably stable at 40–70% from 1993 to 2001. The highest prev-
alence has been reported in Egypt at 75.6% and the lowest 
at 40% in Bahrain. In Jordan, HCV prevalence was 40.5% 
(13), whereas in Lebanon, 14% of patients were positive for 
HCV (25). In Saudi Arabia, a prevalence of 26% was report-
ed in 2002 (30), while in 2011, 1.1% of multitransfused chil-
dren had hepatitis B surface antigen, 3.5% were anti-HCV-
positive, and none were anti-HIV-positive (31). The current 
and future burden of diseases caused by viral hepatitis in 
Egypt is significant. It is not an exaggeration to say that 
viral hepatitis (particularly HCV) is currently and will 
remain Egypt’s most pressing public health issue for 
some time. HBV accounts for 10–30% of chronic liver dis-
ease, and there is a large occult reservoir of HCV causing 
chronic liver disease (32). Omar et al. (33) concluded that 
despite the decrease in HCV antibody prevalence from 
71% to 51.7% in 1995, HCV infection still represents a major 
health problem for patients with thalassemia, which re-
quires more attention and effort. The high prevalence of 
HCV in our study was expected, because the prevalence of 
HCV among the Egyptian population is one of the high-
est in the world. The screening for HCV by ELISA, which is 
used in Egypt, is not very accurate, and many countries 
are using better techniques for screening donated blood 
for viruses by recombinant immunoblot assay and poly-
merase chain reaction techniques. Moreover, the donor 
could be in a window period during which infection may 
not be detected serologically (34). In our study, 39% of pa-
tients with hemophilia were HCV positive, which is low-
er than what was found in a study conducted in Brazil, 
whereas 44.6% of the hemophilic population was positive 
(35), but higher than the results found by Asif et al. (36), 
in Pakistan, where 36% of patients with hemophilia A and 
B tested positive for the hepatitis C antibody. Rezvan et 
al . (37) reported that the prevalence of anti-HCV in pa-
tients with hemophilia is significantly higher than that 
in other multitransfused patients. They reported that 
patients with hemophilia are more susceptible to TTIs, 
as their treatment is dependent on the use of large-pool 
coagulation factor concentrates as well as fresh frozen 
plasma and cryoprecipitate. Although HCV transmission 
by blood products is prevented by viral inactivation steps 
now used in the production of plasma-derived factor 
concentrates, transmission remains a problem in many 
areas of the world, particularly in developing countries 
where hemophilia is treated with fresh frozen plasma or 
cryoprecipitate. Approximately 80% of individuals using 
these products are estimated to be HCV infected. Patients 
with hemophilia thus constitute a high-risk group for ac-
quiring HCV infection (38). We conclude from this study 
that despite the reduction in the prevalence of HBV and 
HCV infection among multitransfused children over the 
past few years, the prevalence remains high in Upper 
Egypt. More efforts should be made to ensure complete 
vaccination of children and provide poster doses if need-
ed. Furthermore, blood screening should be performed 
using more advanced techniques. 
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